

## REVIEW

# Absorption of Drugs from the Bladder and Intravesical Chemotherapy

M. Pavone-Macaluso<sup>1</sup> and N. Gebbia<sup>2</sup>

<sup>1</sup>Chair of Surgical Nephrology, Institute of Urology and

<sup>2</sup>Institute of Pharmacology II, University of Palermo, Policlinico Feliciuzza, Palermo, Italy

It is generally not appreciated that the urinary bladder is not only a reservoir but also an organ that is able to absorb various substances through its mucosal lining.

This is not without interest considering that many drugs are occasionally employed for intravesical instillation. In particular, thio-tepa and other anticancer drugs are frequently employed topically for non-invasive papillary bladder tumours with a relatively high rate of successful results. Absorption of thio-tepa can however be followed by severe or even lethal myelotoxicity. Because of this epodyl has been recommended as a substitute for thio-tepa due to its higher molecular weight. The laws governing absorption from the bladder are however poorly understood.

Ancient and recent studies on the permeability of the urinary bladder in mammals have shown that water, electrolytes, dextrose and other organic and inorganic molecules are absorbed through the bladder wall (1, 3, 14, 15, 16). Detailed investigations by Fellows et al. (8) have demonstrated that the permeability of the bladder to water and solutes is greater than that of the skin (by a factor of about a thousand with regard to water) but similar to that of gastric mucosa and other biological membranes. In spite of some conflicting results, it seems that the epithelium of the bladder usually acts as a passive barrier. Transport of water, sodium and other solutes, therefore, is affected primarily by the laws of diffusion along concentration or osmotic gradients and unaffected by metabolic inhibition. No convincing evidence has been put forward in favour of the hypothesis of active transport of solutes across the epithelium. Active transport was postulated only under particular experimental conditions,

such as the use of stripped vesical epithelium in vitro.

No satisfactory explanation has been presented to account for the variable rate of permeability to various drugs, although absorption can be modified by factors such as pH of the solution, molecular weight of the substances concerned etc. The role of molecular weight is not yet clear. Strohmenger (22), - for example, demonstrated that the human bladder can absorb the large molecule of p-aminohippurate but is impermeable to calcium and phosphorus. Permeability to Na<sup>22</sup> is increased during distension (11) or when the bladder contains hypertonic solutions (23), but these aspects need to be clarified by more detailed investigations using substances other than electrolytes. For a comprehensive review of the pertinent literature the reader is referred to the reports by Englund (6), Fellows and Turnbull (9), Mentasti and Gagliardi (17) and Pavone-Macaluso et al. (20). The human bladder shows a permeability to water and sodium similar to that of the other mammalian species, despite some minor differences. This is also true for the rabbit bladder (23) which can therefore be employed for experiments on the absorption of drugs used in humans.

Absorption across the bladder wall is altered in the absence of an intact epithelial layer. Transfer across the vesical mucosa is greatly enhanced if the bladder epithelium is damaged following contact with chemicals, such as dimethylsulphoxide (2) and cyclophosphamide. Instillations of cytotoxic drugs repeated at frequent intervals may therefore be followed by significant absorption even if the first instillation only gives rise to minimal diffusion. Permeability coefficients of human bladder epi-

thelium to tritiated water (THO) and labelled sodium are markedly increased in the presence of urinary infection and after previous radiotherapy. Well differentiated tumours enhance the permeability because of the increase in epithelial surface area. Absorption however is highest if anaplastic carcinoma is present (7). This latter finding is consistent with the observation that tight intercellular junctions are lacking in undifferentiated tumours, so that the intercellular spaces communicate freely with the bladder lumen.

Practical implications of studies on bladder permeability are mainly related to the use of intravesical instillations of thio-tepa or other anticancer drugs, either as a treatment of multiple papillomas and diffuse papillomatosis or as a measure for achieving a decrease of recurrence rate after successful transurethral removal of papillary bladder tumours. Severe myelotoxicity and even death from generalised sepsis may follow intravesical treatment with thiotepa (4, 24). Experimental data on the absorption of thiotepa from the bladder wall are scarce. Georgacopulo et al. (10) demonstrated that thiotepa labelled with  $S^{35}$  is absorbed from the dog's bladder and can be found in the muscular layer and in the hypogastric lymph nodes. Cole et al. (5) observed that thiotepa can be detected in peripheral blood following intravesical instillation in dogs. Absorption was greater if the urine was alkaline. Lunglmayr and Czech (12) demonstrated that absorption of thiotepa from the human bladder can reach 38% of the administered dose in the presence of large papillary tumours, 58% in cases of diffuse papillomatosis, 47% in cases of cystitis and as much as 91% following transurethral surgery. Absorption of thio-tepa can be enhanced if a hyperthermic solution is employed, as suggested by Lunglmayr et al. (13) or if vesico-ureteric reflux is present (18).

Other drugs have been successfully used by intravesical instillation, although the overall experience is still limited. Epodyl (21), adriamycin, daunomycin, VM26, Peptichemio and other drugs were found capable of inducing regression of already established tumours or of reducing recurrence rate (19). No myelotoxicity was ever observed after instillations of drugs other than thiotepa, but almost nothing is known about their absorption.

In conclusion, it seems that our present knowledge of the absorption of drugs from the bladder is incomplete. Further studies are necessary considering the importance of the practical implications, especially in the field of topical chemotherapy.

## REFERENCES

1. Bartz, L., Harten, M., Walzer, M.: Absorption of proteins through the human bladder. *Journal of Urology* 50, 71 (1943)
2. Borzelleca, J.F., Harries, J.M., Bernstein, S.: The effect of DMSO on the permeability of the urinary bladder. *Investigative Urology* 6, 43 (1968)
3. Brian, G.T., Morris, C.R.: Production of experimental bladder tumors. III. Absorption of  $C^{14}$  labelled 3-hydroxy-L-kynurenine and 3-hydroxyanthranilic acid from the mouse bladder. *Proceedings of the American Association for Cancer Research* 6, 8 (1965)
4. Bruce, D.W., Edgcomb, J.H.: Pancytopenia and generalized sepsis following treatment of cancer of bladder with instillations of triethylene-thiophosphoramidate. *Journal of Urology* 97, 482 (1967)
5. Cole, D.R., Howley, T., Rowan, R., Dreyer, B., Tan, Y.L., Gonzales, E., Rousselot, L.M.: Absorption and activity studies on intraluminal thio-tepa in the dog's bladder. *Journal of Urology* 94, 556 (1965)
6. Englund, S.E.: Observation on the migration of some labelled substances between the urinary bladder and the blood. *Acta radiologica Scandinavica Suppl.* 135 (1956)
7. Fellows, G.J.: Permeability of normal and diseased human bladder epithelium. *Proceedings of the Royal Society of Medicine* 65, 299 (1972)
8. Fellows, G.J., Marshall, D.H.: The permeability of human bladder epithelium to water and sodium. *Investigative Urology* 9, 339 (1972)
9. Fellows, G.J., Turnbull, G.J.: The permeability of mammalian urinary bladder epithelium. *Revue européenne d'Études cliniques et biologiques* 16, 303 (1971)
10. Georgacopulo, T., Stancanelli, V., Fresu, I.: Modalità di riassorbimento di una mostarda azotata introdotta nella vescica. *Minerva chirurgica* 19, 693 (1964)
11. Hakim, A.A., Lifson, N., Creevy, C.D.: Fluxes of  $Na^+$  and  $Cl^-$  in the dog urinary bladder. *Investigative Urology* 2, 348 (1965)
12. Lunglmayr, G., Czech, K.: Absorption studies on intraluminal thio-tepa for topical cytostatic treatment of low-stage bladder tumors. *Journal of Urology* 106, 72 (1971)
13. Lunglmayr, G., Czech, K., Weissenhofer, W., Kellner, G., Zeckert, F.: Experimentelle Untersuchungen über die Wirkung temporärer Hyperthermie auf Blasentumore. *Urologia internationalis* 28, 314 (1973)
14. Macht, D.I.: Absorption of drugs through the bladder. *Journal of Urology* 2, 211 (1918)

15. Maluf, N.S.R.: Absorption of water, urea, glucose and electrolytes through the bladder. *Journal of Urology* 69, 396 (1953)
16. Maluf, N.S.R.: Further studies on absorption through the human bladder. *Journal of Urology* 73, 830 (1955)
17. Mentasti, P., Gagliardi, F.: Assorbimento della vescica umana per il P<sup>32</sup>. *Ostetricia e Ginecologia* 13, 217 (1967)
18. Orlin, I.: The role of cystography in thiotepa toxicity. *Journal of Urology* 108, 257 (1972)
19. Pavone-Macaluso, M.: Chemotherapy of bladder tumours. Report 16th Congr. Int. Soc. Urol. Doin, Paris Vol. I, p. 234 (1973)
20. Pavone-Macaluso, M., Caramia, G., Rizzo, F.P., Ascoli, R., Gebbia, N., Biondo, F., Butera, G., Mazzaresse, S.: L'assorbimento dei farmaci attraverso la vescica. Esperienze sugli antiblastici. *Recenti progressi in medicina* (in press)
21. Riddle, P.R.: The management of superficial bladder tumours with intravesical epodyl. *British Journal of Urology* 45, 84 (1973)
22. Strohmenger, P., Sack, H.: Resorption radioaktiv markierter Substanzen aus Harnblase und isolierter Dünndarmschlinge. *Urologia internationalis* 21, 538 (1966)
23. Turnbull, G.J., Fellows, G.J.: Permeability of the urinary bladder of the rabbit. *Revue européenne d'Études cliniques et biologiques* 17, 745 (1972)
24. Watkins, W.E., Kozak, J.A., Flanagan, M.J.: Severe pancytopenia associated with use of intravesical thiotepa. *Journal of Urology* 98, 470 (1967)

M. Pavone-Macaluso, M.D.  
Chair of Surgical Nephrology  
Institute of Urology  
University of Palermo  
Policlinico Feliciuzza  
I-90127 Palermo  
Italy